ArticleFrontiers in immunology2021
Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Integrative Multidimensional Profiling of Individuals Recovered from Mild COVID-19 Reveals Immune-Metabolic-Oxidative Network Interactions.International journal of molecular sciences · 2026Article
- Benchtop NMR as a clinical tool for acute respiratory illness: metabolic signatures associated with disease severity.Respiratory research · 2026Article
- Article
- Metabolomics and Cytokine Signatures in COVID-19: Uncovering Immunometabolism in Pathogenesis.Metabolites · 2025Article
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.Nature communications · 2024Article
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.medRxiv : the preprint server for health sciences · 2024Article
- Stratification of hypertension and SARS-CoV-2 infection by quantitative NMR spectroscopy of human blood serum.Communications medicine · 2023Article
- NMR Metabolomics Methods for Investigating Disease.Analytical chemistry · 2023Review
- NMR-Metabolomics in COVID-19 Research.Advances in experimental medicine and biology · 2023Article
- Metabolism of NK cells during viral infections.Frontiers in immunology · 2023Review
- Metabolomics as a powerful tool for diagnostic, pronostic and drug intervention analysis in COVID-19.Frontiers in molecular biosciences · 2023Review
- Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19.Vaccines · 2022Article
- Progress and Challenges of Point-of-Need Photonic Biosensors for the Diagnosis of COVID-19 Infections and Immunity.Biosensors · 2022Review
- Using Precision Medicine for the Diagnosis and Treatment of Viral Pneumonia.Advances in therapy · 2022Review
- Hematological- and Immunological-Related Biomarkers to Characterize Patients with COVID-19 from Other Viral Respiratory Diseases.Journal of clinical medicine · 2022Article
- A metagenomic DNA sequencing assay that is robust against environmental DNA contamination.bioRxiv : the preprint server for biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Deep understanding of the SARS-CoV-2 effects on host molecular pathways is paramount for the discovery of early biomarkers of outcome of coronavirus disease 2019 (COVID-19) and the identification of novel therapeutic targets. In that light, we generated metabolomic data from COVID-19 patient blood using high-throughput targeted nuclear magnetic resonance (NMR) spectroscopy and high-dimensional flow cytometry. We find considerable changes in serum metabolome composition of COVID-19 patients associated with disease severity, and response to tocilizumab treatment. We built a clinically annotated, biologically-interpretable space for precise time-resolved disease monitoring and characterize the temporal dynamics of metabolomic change along the clinical course of COVID-19 patients and in response to therapy. Finally, we leverage joint immuno-metabolic measurements to provide a novel approach for patient stratification and early prediction of severe disease. Our results show that high-dimensional metabolomic and joint immune-metabolic readouts provide rich information content for elucidation of the host's response to infection and empower discovery of novel metabolic-driven therapies, as well as precise and efficient clinical action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.